Ireland's First Psychedelic Conference Explores Substances As Mental Health Treatment

Trinity College Dublin is hosting Ireland’s inaugural psychedelics conference, highlighting emerging research on psychedelic substances as potential treatments for mental health conditions.

The conference, held in collaboration with Irish Doctors for Psychedelic Assisted Therapy, also marks the launch of Trinity’s new Psychedelic Research Group (PRG). This group aims to advance understanding of psychedelics' therapeutic applications amid growing global interest.

A New Perspective On Psychedelic Therapy

As Newstalk reported, Dr. Kathryn Ledden, a member of Trinity's PRG, spoke about the potential benefits psychedelics could offer, despite their current legal status in Ireland. "There is mounting evidence internationally and at home," Dr. Ledden noted, suggesting that psychedelics might have "therapeutic benefits" for people dealing with mental health issues and addictions. However, she acknowledged that deep-rooted skepticism about psychedelics remains, given their psychoactive effects.

See Also: Weed, Fear And Control This Halloween: Conservatives Revive Zombie Myths To Hijack The Debate

Dr. Ledden emphasized that modern psychedelic trials differ greatly from past experimentation, stressing rigorous protocols and the use of therapies to support participants. “These trials are conducted in very rigorously controlled environments with therapies, including psychotherapy, as well as structured follow-ups to ensure that people are safe after taking these things,” she explained.

Challenges In Psychedelic Research

Dr. Ledden pointed to the unique challenges in studying psychedelics within traditional clinical frameworks, where substances are typically evaluated using double-blind, placebo-controlled trials. “Because of the psychoactive nature of these substances, it’s quite difficult to study them in terms of the typical clinical standard,” she said. Nonetheless, the efficacy of psychedelics in addressing conditions like treatment-resistant depression and anorexia nervosa has shown promise, inspiring Trinity College's public study on psilocybin's effects on cocaine use disorders.

Momentum Grows, But Caution Advised

While the PRG advocates for further research, Dr. Ledden maintains that psychedelics are not suitable for everyone. “There are some people who shouldn’t take psychedelics,” she said, highlighting individuals with severe mental health disorders, such as bipolar disorder, psychosis, or schizophrenia. These conditions may interact unpredictably with psychedelics, affecting individuals’ perceptions of themselves and the world around them.

The conference signals a shift in Ireland's scientific community, with researchers and medical professionals increasingly interested in exploring psychedelics' potential benefits. In the same way, the Oireachtas Joint Committee on Drugs Use published days ago its interim report responding to 36 recommendations of the Citizens’ Assembly on Drug Use, among which is the decriminalization of personal use and possession of illegal drugs. The publication comes about nine months after the Citizens’ Assembly issued a report recommending drug decriminalization.

Beyond this, as Dr. Ledden concluded, there is much to learn before psychedelics could achieve mainstream therapeutic use, emphasizing the importance of ongoing studies to uncover the full scope and safety of these promising treatments.

Cover image made with AI